All In Biotech

Drug Trial Radar · NCT05712200

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Dec 27, 2022

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Anthos Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Novartis Pharmaceuticals
First posted
Feb 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

Conditions

  • Atrial Fibrillation (AF)

Interventions

  • AbelacimabBiological

    Abelacimab provided as liquid in vial (150 mg/mL)

  • PlaceboDrug

    Dosage Formulation: Liquid (in vial) Dose Strength: Placebo to Abelacimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)Time frame: Up to 30 months
  2. Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleedingTime frame: Up to 30 months

Locations

789 sites in 35 countries. Site status is shown where the registry gives one.

  • Anthos Investigative Site 1040

    Birmingham, Alabama · Recruiting

  • Anthos Investigational site 9939

    Birmingham, Alabama · Recruiting

  • Anthos Investigative Site 9947

    Birmingham, Alabama · Not yet recruiting

  • Anthos Investigative Site 1041

    Mobile, Alabama · Recruiting

  • Anthos Investigative Site 1089

    Gilbert, Arizona · Withdrawn

  • Anthos Investigative Site 1099

    Peoria, Arizona · Recruiting

  • Anthos Investigative Site 9906

    Phoenix, Arizona · Recruiting

  • Anthos Investigative Site 9927

    Yuma, Arizona · Recruiting

  • Anthos Investigative Site 9929

    Huntington Beach, California · Recruiting

  • Anthos Investigative Site 9959

    Imperial, California · Recruiting

  • Anthos Investigative Site 9921

    Lancaster, California · Recruiting

  • Anthos Investigative Site 1078

    Loma Linda, California · Recruiting

  • Anthos Investigative Site 1077

    Los Angeles, California · Recruiting

  • Anthos Investigative Site 1015

    Northridge, California · Withdrawn

  • Anthos Investigational site 9821

    Orange, California · Recruiting

  • Anthos Investigative Site 1070

    Redding, California · Active not recruiting

  • Anthos Investigative Site 1071

    San Dimas, California · Recruiting

  • Anthos Investigative Site 1076

    Santa Ana, California · Withdrawn

  • Anthos Investigative Site 9938

    Santa Rosa, California · Recruiting

  • Anthos Investigative Site 9908

    South Gate, California · Recruiting

  • Anthos Investigative Site 9907

    Vista, California · Recruiting

  • Anthos Investigative Site 1095

    Aurora, Colorado · Recruiting

  • Anthos Investigative Site 1049

    Denver, Colorado · Withdrawn

  • Anthos Investigative Site 9922

    Golden, Colorado · Recruiting

  • Anthos Investigative Site 1012

    Stamford, Connecticut · Recruiting

  • Anthos Investigative Site 9934

    Altamonte Springs, Florida · Recruiting

  • Anthos Investigative Site 1013

    Boca Raton, Florida · Recruiting

  • Anthos Investigational site 9810

    Bradenton, Florida · Recruiting

  • Anthos Investigational site 9818

    Clearwater, Florida · Recruiting

  • Anthos Investigative Site 1025

    Clearwater, Florida · Recruiting

  • Anthos Investigative Site 1022

    Clearwater, Florida · Recruiting

  • Anthos Investigative Site 1019

    Daytona Beach, Florida · Recruiting

  • Anthos Investigative Site 9936

    Hialeah, Florida · Recruiting

  • Anthos Investigative Site 9804

    Hollywood, Florida · Recruiting

  • Anthos Investigative Site 1083

    Hollywood, Florida · Recruiting

  • Anthos Investigational site 9808

    Jacksonville, Florida · Recruiting

  • Anthos Investigative Site 1008

    Jacksonville, Florida · Withdrawn

  • Anthos Investigational site 9813

    Jacksonville, Florida · Recruiting

  • Anthos Investigational site 9828

    Jacksonville, Florida · Recruiting

  • Anthos Investigative Site 9904

    Lake Mary, Florida · Recruiting

Showing 40 of 789 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.